Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Gynecol Oncol. 2019 Aug 14;155(1):51–57. doi: 10.1016/j.ygyno.2019.08.006

Table 3:

Multivariate overall survival analysis: long vs. short ICI therapy

Variables HR 95% CI
LB
95% CI
UB
p
ICI therapy:
 Long (≥24wk) vs. short <24wk) ICI duration 0.55 0.23 1.33 0.19
Platinum status at ICI initiation:
 Sensitive vs. resistant/refractory 0.59 0.26 1.36 0.22
Prior Chemo Lines: (continuous variable) 1.19 1.04 1.36 0.012

ICI, immune checkpoint inhibitor